Clinical Outcome of Intraperitoneal Hyperthermic Perfusion Combined with Surgery for Gastric Cancer with Peritoneal Dissemination or Serosal Invasion

Abstract

Intraperitoneal hyperthermic perfusion (IPHP) combined with surgery was performed for 31 gastric cancer patients with peritoneal dissemination and/or serosal inasion. The clinical results of this IPHP treatment were compared with findings in 30 gastric cancer patients with much the same background factors who underwent surgery alone within the same period of time (control group). The survival rates for the IPHP group surpassed those for the control group at p=1.46 × 10^-4. One-, two-, and three-year survival rates for the IPHP group were 81.9%, 52.1%, and 26.1%, respectively, whereas those for the control group were 40.3%, 11.8%, and 0%, respectively. Survival rates of 21 patients with peritoneal dissemination given IPHP were better than 9 patients not given IPHP, with p=2.37 × 10^-5. The IPHP and control groups with serosal invasion included 10 and 21 patients, respectively, and the survival rates for the former was superior to that of the latter, with a significantly statistical difference at p=0.0153. The incidence of death due to peritoneal recurrence was 6.5% (2/31 patients) in the IPHP group and 63.3% (19/30 patients) in the control group, and the difference being significant at p=2.27 × 10^-6. These results show that the combination of surgery and IPHP is efficacious for far-advanced gastric cancer with peritoneal dissemination and/or serosal invasion.